2-(2,3,5,6-tetrafluoro-2'-methoxybiphenyl-4-ylcarbamoyl)cyclopent-1-enecarboxylic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2,3,5,6-tetrafluoro-2'-methoxybiphenyl-4-ylcarbamoyl)cyclopent-1-enecarboxylic acid
• 英文别名: 2-((2,3,5,6-tetrafluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)carbamoyl)cyclopent-1-enecarboxylic acid；2-(2,3,5,6-Tetrafluoro-2'-methoxy-biphenyl-4-ylcarbamoyl)-cyclopent-1-enecarboxylic acid；2-{[2,3,5,6-Tetrafluoro-4-(2-methoxyphenyl)phenyl]carbamoyl}cyclopent-1-ene-1-carboxylic acid；2-[[2,3,5,6-tetrafluoro-4-(2-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid
• 化学式: C₂₀H₁₅F₄NO₄
• 分子量: 409.337
• InChiKey: HCXILGIDNGULJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-溴-2,3,5,6-四氟苯胺 在 potassium fluoride 、 钯 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 2-(2,3,5,6-tetrafluoro-2'-methoxybiphenyl-4-ylcarbamoyl)cyclopent-1-enecarboxylic acid
  参考文献：
  名称：

  Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement

  摘要：

  A novel series of DHODH inhibitors was developed based on a lead which was obtained by a docking procedure and a medicinal chemistry exploration. The activity of the initial lead was improved by a QSAR method to yield low nanomolar inhibitors. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.021

文献信息

• Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
  申请人：4SC AG

  公开号：US20030203951A1

  公开（公告）日：2003-10-30

  The present invention relates to novel compounds that can be used as antiinflammatory, immunomodulatory and antiproliferatory agents. In particular the invention refers to new compounds which inhibit dihydroorotate dehydrogenase (DHODH), a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).

  本发明涉及可用作抗炎、免疫调节和抗增殖剂的新化合物。具体而言，该发明涉及抑制二氢乳酸脱氢酶（DHODH）的新化合物，以及制造它们的方法、含有它们的药物组合物，以及它们用于治疗和预防疾病的用途，特别是在需要抑制二氢乳酸脱氢酶（DHODH）的疾病中的用途。
• Methods for treatment of melanoma
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US10016402B2

  公开（公告）日：2018-07-10

  Embodiments of the present invention are directed to methods for treatment of melanoma using an inhibitor of dihydroorotate dehydrogenase (DHODH) and to combination therapies that involve administering to a subject an inhibitor of oncogenic BRAF (e.g. BRAF(V600E)), as well as an inhibitor of dihydroorotate dehydrogenase (DHODH). Assays for identifying compounds useful for the treatment of melanoma are also provided. The methods comprise screening for compounds or agents that inhibit neural crest progenitor formation in a zebra fish model of melanoma.

  本发明的实施方案涉及使用二氢烟酸脱氢酶(DHODH)抑制剂治疗黑色素瘤的方法，以及涉及向受试者施用致癌BRAF(例如BRAF(V600E))抑制剂以及二氢烟酸脱氢酶(DHODH)抑制剂的联合疗法。还提供了用于鉴定治疗黑色素瘤的化合物的检测方法。这些方法包括在黑色素瘤斑马鱼模型中筛选抑制神经嵴祖细胞形成的化合物或制剂。
• DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS
  申请人：Panoptes Pharma Ges.m.b.H.

  公开号：EP2427186B1

  公开（公告）日：2022-01-12
• NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS
  申请人：4SC AG

  公开号：EP1392642A2

  公开（公告）日：2004-03-03
• NOVEL SALTS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS
  申请人：4SC AG

  公开号：EP2588447A1

  公开（公告）日：2013-05-08